Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CASM regulates lysosomal expansion and cell fate during senescence
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel
View: Text | PDF
Research Article Aging Cell biology

CASM regulates lysosomal expansion and cell fate during senescence

  • Text
  • PDF
Abstract

Cellular senescence, a hallmark of aging, is accompanied by a striking expansion of the cell’s lysosomal compartment, yet the pathway leading to increased lysosomal content remains unresolved. Here, we demonstrate that the master lysosomal transcriptional regulator TFEB is activated during senescence through a pathway that involves conjugation of ATG8 onto single membranes (CASM). Using various senescence inducers, we show that senescence induction triggers robust TFEB nuclear translocation and upregulation of TFEB target genes. In contrast, inhibition of the core CASM machinery by CRISPR-mediated deletion of either ATG16L1, ATG12, or ATG5 markedly reduced senescence-induced TFEB nuclear translocation. In ATG16L1-KO cells, reconstitution with WT ATG16L1 but not the CASM-defective ATG16L1F467A mutant restored both ATG8 lipidation on the lysosomal surface and TFEB activation. Moreover, expression of the Salmonella effector protein SopF, a previously described specific CASM inhibitor, similarly blocked senescence-induced TFEB translocation. Functionally, upon stress, CASM-deficient cells exhibited a pronounced shift away from senescence and toward a cell death fate, a phenotype reversed by expressing a constitutively active form of TFEB. Together, these findings identify CASM-dependent TFEB activation as an essential mechanism enabling senescence-associated lysosomal expansion and suggest that lysosomal capacity modulates cell fate decisions in the aftermath of acute stress.

Authors

Yu-Wei Cheng, Michael Z. Gao, Jay Xiaojun Tan, Jie Liu, Toren Finkel

×

Figure 5

A role for TFEB and lysosomal capacity in senescent cell fate decisions.

Options: View larger image (or click on image) Download as PowerPoint
A role for TFEB and lysosomal capacity in senescent cell fate decisions....
(A) Immunoblot analysis of lysosomal expansion in WT, ATG16L1-KO, or ATG16L1-KO + TFEBS142A cells on Day 0 (untreated) and Day 3 after senescence induction with 100 nM DOX using LAMP1/ cathepsin B/β-galactosidase expression as markers of lysosomal content. β-Actin is used as a loading control. Blots are representative of n = 3 independent experiments. (B and C) Cell death analysis and viability quantification of WT, ATG16L1-KO cells, and ATG16L1-KO BEAS-2B cells expressing constitutively active TFEBS142A before and 3 days after senescence induction with 100 nM doxorubicin. Flow cytometry plots in B are representative of n = 4 independent experiments. In C, data are mean ± SD; statistical significance was determined by 1-way ANOVA followed by Dunnett’s multiple-comparison test against WT. ***P < 0.001; ns, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts